Amend | Jotup

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Tuesday, December 21, 2021

Biotechnology, Pharmaceutical, Health, Medication, Financial compensation, Board, Security (finance), Arena Pharmaceuticals, U.S. Securities and Exchange Commission, Nasdaq, Private Securities Litigation Reform Act, Employment, Amend, RSU, Patient, Public relations

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs").

Key Points:

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs").
The inducement RSUs have a grant date and vesting commencement date of December 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2021 Long-Term Incentive Plan.
ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients.

Enviva Increases Revolver Capacity

Retrieved on:

Monday, December 20, 2021

Enviva (NYSE: EVA) aggregates a natural resource, wood fiber, and processes it into a transportable form, wood pellets.

Key Points:

Enviva (NYSE: EVA) aggregates a natural resource, wood fiber, and processes it into a transportable form, wood pellets.
Enviva owns and operates 10 plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi.
Follow Enviva on social media @Enviva.
Enviva cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Enviva.

RRD Board Unanimously Determines that Chatham’s Unsolicited Proposal to Acquire RRD for $10.85 Per Share in Cash Constitutes a “Superior Proposal”

Retrieved on:

Friday, December 10, 2021

Under the terms of the Amended Agreement, affiliates of Atlas have agreed to acquire the Company for $10.35 per share in cash.

Key Points:

Under the terms of the Amended Agreement, affiliates of Atlas have agreed to acquire the Company for $10.35 per share in cash.
Our Board and management team remain committed to acting in the best interests of RRD and all its stockholders, and will continue to take actions to achieve this objective.
RRD has notified Atlas of the Boards determination that the Revised Chatham Proposal constitutes a Superior Proposal and that RRD intends to terminate the Amended Agreement for the purpose of entering into a definitive merger agreement with affiliates of Chatham.
There can be no assurance that Atlas will seek to negotiate with RRD or will make a revised proposal.

Baidu Announces Results of Extraordinary General Meeting

Retrieved on:

Tuesday, December 7, 2021

Baidu, Registrar of Companies, Amend, Cayman Islands, Company, NASDAQ, BIDU, Technology, AI, Adoption, HKEX, Cryptocurrency

BEIJING, Dec. 7, 2021 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that each of the following proposed resolutions submitted for shareholder approval has been duly adopted at its extraordinary general meeting of shareholders held in Beijing today:

Key Points:

BEIJING, Dec. 7, 2021 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that each of the following proposed resolutions submitted for shareholder approval has been duly adopted at its extraordinary general meeting of shareholders held in Beijing today:
as a special resolution, THAT the name of the Company be changed from "Baidu, Inc." to "Baidu, Inc. " by adopting the dual foreign name "";
THAT the registered office provider of the Company be and is hereby authorized to file any and all documents in relation of adoption of the Company's dual foreign name and the adoption of the Amended M&AA with the Registrar of Companies in the Cayman Islands; and the Hong Kong registered office provider of the Company be and is hereby authorized to file any and all documents in relation of the adoption of the Amended M&AA with the Registrar of Companies in Hong Kong accordingly.
Founded in 2000, Baidu's mission is to make the complicated world simpler through technology.
Baidu is a leading AI company with strong Internet foundation, trading on the NASDAQ under "BIDU" and HKEX under "9888."
One Baidu ADS represents eight Class A ordinary shares.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Wednesday, December 1, 2021

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

Key Points:

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting start-up activities for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM.
Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates.

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Tuesday, November 16, 2021

Biotechnology, Pharmaceutical, Health, Security (finance), Cyprus Securities and Exchange Commission, Board, Arena Pharmaceuticals, Private Securities Litigation Reform Act, Nasdaq, Patient, Employment, Financial compensation, Amend, RSU, Medication

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units ("RSUs").

Key Points:

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units ("RSUs").
The inducement stock options and RSUs have a grant date and vesting commencement date of November 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2021 Long-Term Incentive Plan.
ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients.

GetSwift Reports Fiscal First Quarter 2022, Swings to Profit

Retrieved on:

Monday, November 15, 2021

We saw a 64% improvement in revenue from customer contracts over the prior quarter, building on 67% growth in the prior quarter, while we continued to reduce operating costs.

Key Points:

We saw a 64% improvement in revenue from customer contracts over the prior quarter, building on 67% growth in the prior quarter, while we continued to reduce operating costs.
The Corporation expects that the subsequent third quarter ending in March 2022 will see an increase over the second quarter in revenue.
Total operating expenses for the first quarter of 2022 were $8.9 million as compared to total operating expenses of $14.0 million for the first quarter of fiscal 2021.
Total comprehensive loss for the first quarter of 2022 was $1.9 million, as compared to a total comprehensive loss of $2.2 million for the first quarter of fiscal 2021.

GetSwift Reports Fiscal First Quarter 2022 Financial Results

Retrieved on:

Friday, November 12, 2021

GetSwift Technologies Limited ("GetSwift" or the "Corporation"; NEO: GSW), a leading provider of last mile SaaS logistics technology and services, has reported its financial and operational results for the fiscal first quarter of 2022 which ended September 30, 2021.

Key Points:

GetSwift Technologies Limited ("GetSwift" or the "Corporation"; NEO: GSW), a leading provider of last mile SaaS logistics technology and services, has reported its financial and operational results for the fiscal first quarter of 2022 which ended September 30, 2021.
The Corporation expects that the subsequent third quarter ending in March 2022 will see an increase over the second quarter in revenue.
Total operating expenses for the first quarter of 2022 were $8.9 million as compared to total operating expenses of $14.0 million for the first quarter of fiscal 2021.
Total comprehensive loss for the first quarter of 2022 was $1.9 million, as compared to a total comprehensive loss of $2.2 million for the first quarter of fiscal 2021.

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Retrieved on:

Monday, November 1, 2021

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.

Key Points:

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised.
Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics expects to start SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM in Q4 2021.
Examples of such statements include, but are not limited to, statements relating toCytokinetics'and its partners' research and development activities of Cytokinetics product candidates.

Viston United Swiss AG Commences All-Cash Offer to Acquire Petroteq Energy Inc.

Retrieved on:

Monday, October 25, 2021

Viston United Swiss AG (Viston) and its indirect, wholly-owned subsidiary, 2869889 Ontario Inc. (the Offeror) today announced that the Offeror has commenced a formal offer (the Offer) to acquire all of the issued and outstanding common shares (the Common Shares) of Petroteq Energy Inc. (Petroteq) (TSX-V:PQE; OTC:PQEFF; FSE:PQCF).

Key Points:

Viston United Swiss AG (Viston) and its indirect, wholly-owned subsidiary, 2869889 Ontario Inc. (the Offeror) today announced that the Offeror has commenced a formal offer (the Offer) to acquire all of the issued and outstanding common shares (the Common Shares) of Petroteq Energy Inc. (Petroteq) (TSX-V:PQE; OTC:PQEFF; FSE:PQCF).
The Offer to Purchase and Circular (the Offer to Purchase and Circular) and related documents were mailed to Petroteq shareholders (Shareholders) on October 25, 2021 and the Offer commenced the same day.
Subject to future developments, Viston (and, if applicable, Petroteq) may file additional documents with the Securities and Exchange Commission (the SEC).
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities.